These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 36370191)

  • 21. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis.
    Nieto Y; Gruschkus S; Valdez BC; Jones RB; Anderlini P; Hosing C; Popat U; Qazilbash M; Kebriaei P; Alousi A; Saini N; Srour S; Rezvani K; Ramdial J; Barnett M; Gulbis A; Shigle TL; Ahmed S; Iyer S; Lee H; Nair R; Parmar S; Steiner R; Dabaja B; Pinnix C; Gunther J; Cuglievan B; Mahadeo K; Khazal S; Chuang H; Champlin R; Shpall EJ; Andersson BS
    Haematologica; 2022 Apr; 107(4):899-908. PubMed ID: 33951890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience.
    Moretti M; Liberati AM; Rigacci L; Puccini B; Pulsoni A; Gini G; Galieni P; Fabbri A; Cantonetti M; Pavone V; Bolis S; Botto B; Renzi D; Falchi L
    Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):198-204. PubMed ID: 34690088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.
    Herrera AF; Palmer J; Martin P; Armenian S; Tsai NC; Kennedy N; Sahebi F; Cao T; Budde LE; Mei M; Siddiqi T; Popplewell L; Rosen ST; Kwak LW; Nademanee A; Forman SJ; Chen R
    Ann Oncol; 2018 Mar; 29(3):724-730. PubMed ID: 29272364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting.
    Nademanee A; Sureda A; Stiff P; Holowiecki J; Abidi M; Hunder N; Pecsok M; Uttarwar M; Purevjal I; Sweetenham J
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2354-2359. PubMed ID: 29859255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).
    Garcia-Sanz R; Sureda A; de la Cruz F; Canales M; Gonzalez AP; Pinana JL; Rodriguez A; Gutierrez A; Domingo-Domenech E; Sanchez-Gonzalez B; Rodriguez G; Lopez J; Moreno M; Rodriguez-Salazar MJ; Jimenez-Cabrera S; Caballero MD; Martinez C
    Ann Oncol; 2019 Apr; 30(4):612-620. PubMed ID: 30657848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era.
    Varma G; Diefenbach C
    Semin Hematol; 2024 Aug; 61(4):253-262. PubMed ID: 39039012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
    Moskowitz AJ; Schöder H; Yahalom J; McCall SJ; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz S; Kobos R; Kumar A; Matasar M; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Shukla N; Steinherz P; Straus D; Trippett T; Younes A; Zelenetz A; Moskowitz CH
    Lancet Oncol; 2015 Mar; 16(3):284-92. PubMed ID: 25683846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
    Moskowitz AJ; Schöder H; Gavane S; Thoren KL; Fleisher M; Yahalom J; McCall SJ; Cadzin BR; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz SM; Kumar A; Matasar M; Ni A; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Straus D; Younes A; Zelenetz AD; Moskowitz CH
    Blood; 2017 Nov; 130(20):2196-2203. PubMed ID: 28874350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Successful treatment with brentuximab vedotin maintenance therapy after autologous stem cell transplantation in high-risk Hodgkin lymphoma].
    Ishii K; Azuma Y; Konishi A; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Nakaya A; Fujita S; Satake A; Miyaji M; Ito T; Nomura S
    Rinsho Ketsueki; 2018; 59(8):1002-1006. PubMed ID: 30185698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
    Bröckelmann PJ; Zagadailov EA; Corman SL; Chirikov V; Johnson C; Macahilig C; Seal B; Dalal MR; Illidge T
    Eur J Haematol; 2017 Dec; 99(6):553-558. PubMed ID: 28949403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
    Herrera AF; Chen L; Nieto Y; Holmberg L; Johnston P; Mei M; Popplewell L; Armenian S; Cao T; Farol L; Sahebi F; Spielberger R; Chen R; Nademanee A; Puverel S; Nwangwu M; Lee P; Song J; Skarbnik A; Kennedy N; Peters L; Rosen ST; Kwak LW; Forman SJ; Feldman T
    Lancet Haematol; 2023 Jan; 10(1):e14-e23. PubMed ID: 36403579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany.
    Zagadailov EA; Corman S; Chirikov V; Johnson C; Macahilig C; Seal B; Dalal MR; Bröckelmann PJ; Illidge T
    Leuk Lymphoma; 2018 Jun; 59(6):1413-1419. PubMed ID: 29045163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.
    Scott LJ
    Drugs; 2017 Mar; 77(4):435-445. PubMed ID: 28190142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.
    Bonthapally V; Yang H; Ayyagari R; Tan RD; Cai S; Wu E; Gautam A; Chi A; Huebner D
    Curr Med Res Opin; 2015; 31(7):1377-89. PubMed ID: 25950500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents.
    Shah H; Jang H; Singh P; Kosti J; Kin A; Alavi A; Ratanatharathorn V; Ayash L; Uberti J; Ramchandren R; Kim S; Deol A
    Leuk Lymphoma; 2022 Apr; 63(4):813-820. PubMed ID: 34781825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review.
    Arabloo J; Azari S; Gorji HA; Rezapour A; Alipour V; Ehsanzadeh SJ
    Eur J Clin Pharmacol; 2023 Nov; 79(11):1443-1452. PubMed ID: 37656182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure.
    Ueda N; Kato H; Kato S; Saito T; Tachibana H; Yanada M; Taji H; Kodaira T; Hosoda W; Yamamoto K
    Hematology; 2023 Dec; 28(1):2207946. PubMed ID: 37183912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.